|Bid||0.00 x 28400|
|Ask||0.00 x 2100|
|Day's range||108.35 - 110.05|
|52-week range||86.03 - 123.90|
|PE ratio (TTM)||18.77|
|Earnings date||20 Feb 2018 - 26 Feb 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||120.92|
Oct.26 -- Bayer AG is teaming up with Ginkgo Bioworks, a Boston-based biotechnology company, on a record $100-million wager on farming technology. The seeds for bets like these are sewn at the Bayer Lifescience Center in Cambridge, Massachusetts. Bloomberg's Anne Mostue reports.
Brazilian antitrust agency Cade on Wednesday extended its deadline to review the takeover of Monsanto Co (MON.N) by Bayer AG (BAYGn.DE) by 90 days to late March, potentially spoiling plans to wrap up the $66 billion (£49.60 billion) tie-up by the end of the year. Bayer and Monsanto declined to comment on the decision. Brazil is Monsanto's biggest market outside of the United States.
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- UK oil company BP and holding company Bridas Corp to acquire oil ...
German drugmaker Bayer (BAYGn.DE) has hired the head of Nestle's (NESN.S) baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon (AMZN.O) and other online platforms. Bayer has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday. Bayer was caught off guard by the speed of U.S. consumers switching to online stores at the expense of established drugstores.
German drugmaker Bayer (Swiss: BAYN-EUR.SW - news) has hired the head of Nestle's baby food business to help it reverse a drop in revenue from consumer health brands, which often fail to appeal to buyers on Amazon and other online platforms. Bayer (IOB: 0P6S.IL - news) has appointed Nestle's Heiko Schipper, 48, to run the Consumer Health division as a group board member from March 1 next year, replacing Erica Mann, Bayer said in a statement on Wednesday.
If time is money, big M&A is getting a lot costlier in the European Union thanks to a tactic increasingly deployed by the bloc’s merger watchdogs in Brussels.
A Relative Strength Rating upgrade for Bayer shows improving technical performance. Will it continue?
Bayer (BAYGn.DE) is weighing legal action and Novartis (NOVN.S) has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug. Doctors from 12 clinical commissioning groups (CCG) plan to make Roche's (ROG.S) cancer therapy Avastin the preferred option for wet age-related macular degeneration (AMD), even though it is not licensed for this use. David Hambleton, head of the South Tyneside CCG, said the policy of using Avastin rather than Bayer's Eylea or Novartis's Lucentis could save the regional National Health Service (NHS) 13.5 million pounds a year.
Bayer (IOB: 0P6S.IL - news) is weighing legal action and Novartis (IOB: 0QLR.IL - news) has expressed concern at plans by doctors in the north of England to defy official guidance by using a cancer medicine as a cheap eye drug. Doctors from 12 clinical commissioning groups (CCG) plan to make Roche's cancer therapy Avastin the preferred option for wet age-related macular degeneration (AMD (Shenzhen: 002623.SZ - news) ), even though it is not licensed for this use. David Hambleton, head of the South Tyneside CCG, said the policy of using Avastin rather than Bayer's Eylea or Novartis's Lucentis could save the regional National Health Service (NHS) 13.5 million pounds ($18 million) a year.
The Zacks Analyst Blog Highlights: RWE AG, Daimler AG, Bayer Aktiengesellschaft and Arkema S.A.
Bayer AG's (BAYRY) core earnings per share from continuing operations beat expectations in the third quarter of 2017 and the company lost de facto control over the Covestro Group at the end of the quarter.
Bayer AG, the 154-year-old creator of aspirin, has been ambushed by a growing force: online retailers like Amazon.com Inc.
Bayer (BAYGn.DE) said it expected antitrust authorities to make the planned acquisition of Monsanto (MON.N) conditional on more asset sales after agreeing to sell seed and herbicide businesses for 5.9 billion euro (£5.31 billion) to BASF (BASFn.DE). "By no means did the deal that was signed with BASF constitute the totality of antitrust divestitures ... The agencies will render their verdict on what the necessary remedies are. It's probably a first step and somewhat more is to come," Chief Executive Werner Baumann told an analyst call on Thursday after the release of third-quarter results.
"We will also use the net proceeds from the announced divestiture to BASF to refinance the Monsanto acquisition," Chief Executive Werner Baumann said in prepared remarks published ahead of a conference call for journalists. Bayer has agreed to sell seed and herbicide businesses for 5.9 billion euros ($7 billion) to BASF, which analysts have said was richly priced.
German drugmaker Bayer (BAYGn.DE) has cut the value of its takeover of Monsanto (MON.N) by $2.5 billion (£1.89 billion), which combined with windfalls from asset sales means it may have to raise less than expected from shareholders. The Monsanto deal is now valued at $63.5 billion including debt, down from an initial $66 billion, because the U.S. seeds giant had lowered its financial liabilities, Bayer's finance chief said on Thursday. The planned acquisition will boost Bayer's agriculture sales to the same level as its core healthcare business, but the move has not been universally popular among shareholders and has led those with a pharma focus in particular to sell out.
The Zacks Analyst Blog Highlights: Deutsche Lufthansa, Peugeot, Luxottica, Bayer and Arkema.
German chemicals and pharmaceuticals giant Bayer said group net profit stood at 3.9 billion euros ($4.6 billion) between July and September, more than triple the 1.2 billion euros reported in the same ...
DGAP-News: Topas Therapeutics GmbH / Key word(s): Change of Personnel26.10.2017 / 09:00 The issuer is solely responsible for the content of this announcement.Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., asChief Development Officer and Chief Medical Officer Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering To lead Topas' clinical development and regulatory affairsHamburg, 26 October 2017. ...
The composite PMI reading remained at a level which indicates that economic activity continues to remain firm across the region.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, Monsanto, Adaptimmune Therapeutics and Celgene
Bayer Aktiengesellschaft (BAYRY) inked a deal to sell selected Crop Science businesses to BASF for EUR 5.9 billion to as a part of its strategy to complete the planned acquisition of Monsanto Co.